The role of targeted BRCA1/BRCA2 mutation analysis in hereditary breast/ovarian cancer families of Portuguese ancestry

Clinical Genetics

Volumn 88, Issue 1, 2015, Pages 41-48

  Peixoto, A ^a   Santos, C ^a   Pinto, P ^a   Pinheiro, M ^a   Rocha, P ^a   Pinto, C ^a   Bizarro, S ^a   Veiga, I ^a   Principe, A S ^a   Maia, S ^a   Castro, F ^a   Couto, R ^a   Gouveia, A ^a   Teixeira, M R ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

BRCA1 BRCA2 genes; Founder mutations; Genetic testing criteria and strategy; Portuguese ancestry

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; FAMILIAL CANCER; FAMILY; FEMALE; FOUNDER EFFECT; GENE MUTATION; GENE REARRANGEMENT; GENETIC SCREENING; HAPLOTYPE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; PORTUGUESE (CITIZEN); PRIORITY JOURNAL; CAUCASIAN; GENETIC PREDISPOSITION; GENETICS; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; MALE; MIDDLE AGED; MUTATION; PORTUGAL; TUMOR SUPPRESSOR GENE;

ADULT; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOUNDER EFFECT; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HUMANS; MALE; MIDDLE AGED; MUTATION; PORTUGAL;

EID: 84930416198     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12441     Document Type: Article

References (12)

1. Peixoto A, Santos C, Rocha P et al. The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal. Breast Cancer Res Treat 2009: 114: 31-38.
2. Peixoto A, Santos C, Pinheiro M et al. International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. Breast Cancer Res Treat 2011: 127: 671-679.
3. Teugels E, De Brakeleer S, Goelen G, Lissens W, Sermijn E, De Greve J. De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes. Hum Mutat 2005: 26: 284.
4. De Brakeleer S, De Greve J, Lissens W, Teugels E. Systematic detection of pathogenic alu element insertions in NGS-based diagnostic screens: the BRCA1/BRCA2 example. Hum Mutat 2013: 34: 785-791.
5. Filippini S, Blanco A, Fernandez-Marmiesse A et al. Multiplex SNaPshot for detection of BRCA1/2 common mutations in Spanish and Spanish related breast/ovarian cancer families. BMC Med Genet 2007: 8: 40.
6. Peixoto A, Salgueiro N, Santos C et al. BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families. Fam Cancer 2006: 5: 379-387.
7. Santos C, Peixoto A, Rocha P et al. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families. J Mol Diagn 2014: 16: 324-334.
8. Blesa JR, Garcia JA, Ochoa E. Frequency of germ-line BRCA1 mutations among Spanish families from a Mediterranean area. Hum Mutat 2000: 15: 381-382.
9. Durocher F, Tonin P, Shattuck-Eidens D, Skolnick M, Narod SA, Simard J. Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites. J Med Genet 1996: 33: 814-819.
10. Torres D, Rashid MU, Gil F et al. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat 2007: 103: 225-232.
11. Balmana J, Diez O, Rubio IT, Cardoso F. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2011: 22 (Suppl. 6): vi31-vi34.
12. Mavaddat N, Barrowdale D, Andrulis IL et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012: 21: 134-147.